Literature DB >> 32871766

ERK/AKT Inactivation and Apoptosis Induction Associate With Quetiapine-inhibited Cell Survival and Invasion in Hepatocellular Carcinoma Cells.

Yu-Chang Liu1,2,3, Song-Shei Lin1, Yen-Ju Lee4,5, Jing-Gung Chung6, Zhao-Lin Tan5,6, Fei-Ting Hsu6.   

Abstract

BACKGROUND/AIM: Quetiapine, an atypical antipsychotic, has been encountered as a potential protective agent to suppress various types of tumor growth. However, the inhibitory mechanism of quetiapine in hepatocellular carcinoma (HCC) still remains unclear. The purpose of present study was to investigate the inhibitory mechanism of quetiapine on cell survival and invasion in HCC.
MATERIALS AND METHODS: Changes of apoptotic signaling, migration/invasion ability, and signaling transduction involved in cell survival and invasion were evaluated with flow cytometry, migration/invasion, and western blot assays.
RESULTS: Quetiapine inhibited cell proliferation and migration/invasion in SK-Hep1 and Hep3B cells. Quetiapine induced extrinsic and intrinsic apoptotic pathways. Activation of extracellular signal-regulated kinases (ERK), protein kinase B (AKT), nuclear factor kappa-light-chain-enhancer of activated B cells (NF-ĸB), expression of anti-apoptotic, and metastasis-associated proteins were decreased by quetiapine.
CONCLUSION: The apoptosis induction, the decreased expression of ERK/AKT-mediated anti-apoptotic and the metastasis-associated proteins were associated with quetiapine-inhibited cell survival and invasion in HCC in vitro. Copyright
© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  ERK/AKT activation; Quetiapine; apoptosis; hepatocellular carcinoma

Mesh:

Substances:

Year:  2020        PMID: 32871766      PMCID: PMC7652484          DOI: 10.21873/invivo.12054

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  39 in total

1.  Quetiapine inhibits osteoclastogenesis and prevents human breast cancer-induced bone loss through suppression of the RANKL-mediated MAPK and NF-κB signaling pathways.

Authors:  Hongkai Wang; Weiwei Shen; Xu Hu; Ying Zhang; Yunyun Zhuo; Tao Li; Feng Mei; Xinmin Li; Lan Xiao; Tongwei Chu
Journal:  Breast Cancer Res Treat       Date:  2015-02-10       Impact factor: 4.872

2.  Mcl-1 is an anti-apoptotic factor for human hepatocellular carcinoma.

Authors:  Binje Fleischer; Henning Schulze-Bergkamen; Marcus Schuchmann; Achim Weber; Stefan Biesterfeld; Martina Müller; Peter H Krammer; Peter R Galle
Journal:  Int J Oncol       Date:  2006-01       Impact factor: 5.650

3.  Aripiprazole, an Antipsychotic and Partial Dopamine Agonist, Inhibits Cancer Stem Cells and Reverses Chemoresistance.

Authors:  Shuhei Suzuki; Masashi Okada; Kenta Kuramoto; Hiroyuki Takeda; Hirotsugu Sakaki; Hikaru Watarai; Tomomi Sanomachi; Shizuka Seino; Takashi Yoshioka; Chifumi Kitanaka
Journal:  Anticancer Res       Date:  2016-10       Impact factor: 2.480

4.  Hyperforin Inhibits Cell Growth by Inducing Intrinsic and Extrinsic Apoptotic Pathways in Hepatocellular Carcinoma Cells.

Authors:  I-Tsang Chiang; Wei-Ting Chen; Chih-Wei Tseng; Yen-Chung Chen; Yu-Cheng Kuo; Bi-Jhih Chen; Mao-Chi Weng; Hwai-Jeng Lin; Wei-Shu Wang
Journal:  Anticancer Res       Date:  2017-01       Impact factor: 2.480

5.  Apoptosis induction and AKT/NF-κB inactivation are associated with regroafenib-inhibited tumor progression in non-small cell lung cancer in vitro and in vivo.

Authors:  Mao-Chi Weng; Ming-Hsin Li; Jing Gung Chung; Yu-Chang Liu; Jeng-Yuan Wu; Fei-Ting Hsu; Hsin-Ell Wang
Journal:  Biomed Pharmacother       Date:  2019-06-01       Impact factor: 6.529

6.  Reduced expression of ICE/caspase1 and CPP32/caspase3 in human hepatocellular carcinoma.

Authors:  K Fujikawa; K Shiraki; K Sugimoto; T Ito; T Yamanaka; K Takase; T Nakano
Journal:  Anticancer Res       Date:  2000 May-Jun       Impact factor: 2.480

7.  Sorafenib increases efficacy of vorinostat against human hepatocellular carcinoma through transduction inhibition of vorinostat-induced ERK/NF-κB signaling.

Authors:  Fei-Ting Hsu; Yu-Chang Liu; I-Tsang Chiang; Ren-Shyan Liu; Hsin-Ell Wang; Wuu-Jyh Lin; Jeng-Jong Hwang
Journal:  Int J Oncol       Date:  2014-05-06       Impact factor: 5.650

8.  Amentoflavone Inhibits ERK-modulated Tumor Progression in Hepatocellular Carcinoma In Vitro.

Authors:  Kun-Ching Lee; Jai-Jen Tsai; Chih-Wei Tseng; Yu-Cheng Kuo; Yao-Chen Chuang; Song-Shei Lin; Fei-Ting Hsu
Journal:  In Vivo       Date:  2018 May-Jun       Impact factor: 2.155

9.  Ruscogenin suppressed the hepatocellular carcinoma metastasis via PI3K/Akt/mTOR signaling pathway.

Authors:  Hui Hua; Yu Zhu; Yu-He Song
Journal:  Biomed Pharmacother       Date:  2018-02-23       Impact factor: 6.529

10.  MiRNA199a-3p suppresses tumor growth, migration, invasion and angiogenesis in hepatocellular carcinoma by targeting VEGFA, VEGFR1, VEGFR2, HGF and MMP2.

Authors:  Alip Ghosh; Debanjali Dasgupta; Amit Ghosh; Shrabasti Roychoudhury; Dhiraj Kumar; Mahadeo Gorain; Ramesh Butti; Simanti Datta; Shaleen Agarwal; Subash Gupta; Gopal Krishna Dhali; Abhijit Chowdhury; Thomas D Schmittgen; Gopal C Kundu; Soma Banerjee
Journal:  Cell Death Dis       Date:  2017-03-30       Impact factor: 8.469

View more
  3 in total

1.  Induction of Apoptosis, Inhibition of MCL-1, and VEGF-A Expression Are Associated with the Anti-Cancer Efficacy of Magnolol Combined with Regorafenib in Hepatocellular Carcinoma.

Authors:  Cheng-Hsien Chen; Fei-Ting Hsu; Wei-Lung Chen; Jiann-Hwa Chen
Journal:  Cancers (Basel)       Date:  2021-04-25       Impact factor: 6.639

2.  The inhibitory effect and mechanism of quetiapine on tumor progression in hepatocellular carcinoma in vivo.

Authors:  Chun-Min Su; Song-Shei Lin; Hsiao-Chia Wang; Fei-Ting Hsu; Jing Gung Chung; Li-Cho Hsu
Journal:  Environ Toxicol       Date:  2021-10-09       Impact factor: 4.109

Review 3.  Repurposing Antipsychotics for Cancer Treatment.

Authors:  Nikolaos Vlachos; Marios Lampros; Spyridon Voulgaris; George A Alexiou
Journal:  Biomedicines       Date:  2021-11-28
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.